GEN Exclusives

More »

The Lists

More »
Sep 4, 2012

Top 20 Pharma-Friendly Congress Members

Who accepted the biggest pharmaceutical company contributions? Find out here.

Top 20 Pharma-Friendly Congress Members

These politicians accepted the most pharma dollars toward their campaigns. [© Ljupco Smokovski -]

  • Below is a list of the 20 members of Congress (both Senate and House of Representatives) that have received the most in campaign contributions from pharmaceutical companies during the 2011–2012 election cycle, as recorded by based on data from the Federal Election Commission available as of Aug. 6. Figures reflect contributions from both political action committees (PACs) and individuals giving $200 or more.

  • #20. Rep. Jason Altmire (D-PA)

    Total contributions: $67,500

  • #19. Sen. Ben Nelson (D-NE)

    Total contributions: $70,350

  • #18. Rep. Jim Gerlach (R-PA)

    Total contributions: $73,750

  • #17. Rep. Steny H. Hoyer (D-MD)

    Total contributions: $74,000

  • #16. Rep. Joe Pitts (R-PA)

    Total contributions: $76,000

  • #15. Rep. Dave Camp (R-MI)

    Total contributions: $76,500

  • #13 (tie). Rep. Kevin McCarthy (R-CA)

    Total contributions: $80,500

  • #13 (tie). Sen. Bob Corker (R-TN)

    Total contributions: $80,500

  • #12. Rep. James E. Clyburn (D-SC)

    Total contributions: $81,250

  • #11. Sen. Tom Carper (D-DE)

    Total contributions: $87,050

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »